A Topical Treatment Revolution is on the Horizon for Psoriasis

摘要

Topical steroids have remained a mainstay first-line treatment for psoriasis, but two new drugs in development aim to revolutionize how topical drugs are used in treatment of the disease. “We’ve had a decent amount of minor innovation in psoriasis,” Mark G. Lebwohl, MD, dean for clinical therapeutics and chair emeritus of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, said. “One thing that has troubled many of us is that we don’t like to use steroids on the face or in-tertriginous sites. The problem is the current nonsteroids are not as strong or effective as the strong steroids. But now we have two drugs coming which are about as effective as the moderately potent or even the potent steroids.” The two new drugs — which have both completed phase 3 trials — are tapinarof (Dermavant Sciences), an aryl hydrocarbon receptor modulating agent, and roflumilast (Arcutis Biotherapeutics), a phosphodiesterase type 4 inhibitor. “We are getting two new chemical entities, which is really exciting in dermatology because it doesn’t happen that often, especially in the topical world,” Leon H. Kir-cik, MD, clinical professor of dermatology at Icahn School of Medicine at Mount Sinai and Indiana University Medical Center, as well as medical director for Physicians Skin Care PLLC, DermResearch PLLC and Skin Sciences PLLC, said.